Drug treatment of hypertension in the elderly: A meta-analysis

Annals of Internal Medicine

Volumn 121, Issue 5, 1994, Pages 355-362

  Insua, Jorge T ^a   Sacks, Henry S ^b   Lau, Tai Shing ^c   Lau, Joseph ^d   Reitman, Dinah ^b   Pagano, Daniel ^b   Chalmers, Thomas C ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Centro Neurologico   (Argentina)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; METHYLDOPA; NIFEDIPINE; PINDOLOL; PROPRANOLOL; RESERPINE; SPIRONOLACTONE; TRIAMTERENE;

ADULT; AGED; AGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0028593932     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-121-5-199409010-00008     Document Type: Review

References (110)

1. Applegate WB. Hypertension in elderly patients. Ann Intern Med. 1989;110:901-15.
2. Drizid T, Dannenberg AL. Blood Pressure Levels in Persons 18-74 Years of Age in 1976-80, and Trends in Blood Pressure from 1960-1980 in the United States. Hyattsville, Maryland: U.S. Department of Health and Human Services. DHHS publication no. (PHS) 86-1684; 1986.
3. Applegate WB. Hypertension. In: Hazzard WR, Andres R, Bierman EL, Blass JP, eds. Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill; 1990:484-97.
4. Lew EA. Hypertension and longevity. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1990:175-90.
5. The Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly. JAMA. 1986;256:70-4.
6. Applegate WB, Curb JD. Designing and executing randomized clinical trials involving elderly persons. J Am Geriatr Soc. 1990;38:943-50.
7. Kannry JL, Chalmers TC, Orza M, Reitman D, Brown W. Neglect of the aged in clinical trials [Abstract]. Controlled Clin Trials. 1989;10: 348.
8. Kaplan NM, Lieberman E. Clinical Hypertension. 5th ed. Baltimore: Willams and Wilkins; 1990:5-6.
9. Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ. 1989;298:1356-8.
10. Mattila K, Haavisto M, Rajala S, Heikinheimo R. Blood pressure and five year survival in the very old. Br Med J (Clin Res Ed). 1988;296:887-9.
11. Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old. Am J Epidemiol. 1991;134:29-38.
12. Sorensen KH, Hilden T. Increased total mortality and decreased functional capacity are associated with low systolic blood pressure among elderly women. Scand J Prim Health Care. 1988;6:105-10.
13. Sprackling ME, Mitchell JR, Short AH, Watt G. Blood Pressure reduction in the elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed). 1981;283:1151-3.
14. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-52.
15. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials. 1981;2:31-49.
16. Greenland S. Quantitative methods in the review of the epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
17. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177-88.
20. Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986; 124:719-23.
21. Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med. 1990;9:247-52.
22. Rothman KJ. Modern Epidemiology. Boston: Little Brown;1986:176-236.
23. Dalhof B, Hansson L, Lindholm L, Rastam L, Schcrsten B, Wester PO. STOP-hypertension: Swedish Trial in Old Patients with Hypertension. J Hypertens. 1986;4:511-3.
24. Dalhof B, Hansson L, Lindholm L, Schersten B, Wester PO. STOP-Hypertension - Preliminary communication from the Pilot Study of the Swedish Trial in Old Patients with Hypertension. J Hypertens Suppl. 1987;5:S607-10.
25. Dalhof B, Lindholm LH, Hansson L, Schersten B, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-5.
26. Draper N, Smith H. Applied Regression Analysis. 2d ed. New York: Wiley; 1981.
27. Hamilton M, Thompson EN, Wisniewski TK. The role of blood pressure control in preventing complications of hypertension. Lancet. 1964;1:235-8.
28. Smith WM for the U.S. Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1970:40(Suppl):I98-105.
29. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasability trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann N Y Acad Sci. 1978;304:267-92.
30. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med. 1980;69:725-32.
31. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double-blind control study of antihypertensive agents. I. Comparative effect of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, clorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1961;106:133-48.
32. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Double-blind control study on antihypertensive agents. II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglion blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1962:110:222-9.
33. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Double-blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med. 1962;110:230-5.
34. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-34.
35. Wolf FW, Lindeman RD. Effects of treatment in hypertension. Results of a controlled study. J Chronic Dis. 1966;19:227-40.
36. Control of moderately raised blood pressure. Report of a co-operative randomized controlled trial. Br Med J. 1973;3:434-6.
37. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed). 1985; 291:97-104.
38. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259: 1976-82.
39. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: results from the HAPPHY trial. J Hyperlens. 1987;5:561-72.
40. The IPPPSH Collaborative Group. Cardiovascular ris k and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3:379-92.
41. Staessen J, Amery A, Birkenhager W, Bulpitt CJ, Cox J, de Leeuw P, et al. Syst-Eur-A multicenter trial on the treatment of isolated systolic hypertension in the elderly: First interim report. J Cardiovasc Pharmacol. 1992;19:120-5.
42. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1: 485-9.
43. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409-18.
44. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA. 1982;248:1465-77.
45. Priddle WW, Liu SF, Breithaupt DJ, Grant PG. Amelioration of high blood pressure in the elderly. J Am Geriatr Soc. 1968;16:887-92.
46. Morgan TO, Adams WR, Hodgson M, Gibberd RW. Failure of therapy to improve prognosis in elderly males with hypertension. Med J Austr. 1980;2:27-31.
47. Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study of the treatment of mild hypertension in the aged. Jpn Heart J. 1981;22:75-85.
48. Perry HM, Smith WM, McDonald RH, Black D, Cutler J, Furburg CD, et al. Morbidity and mortality in the Systolic Hypertension Elderly Program (SHEP) pilot study. Stroke. 1989;20:4-13.
49. Langford HG, Stamler J, Wassertheil-Smoller S, Print-as RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986;29:29-52.
50. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45:991-1004.
51. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-71.
52. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race-sex and age. JAMA. 1979;242:2572-7.
53. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in mild hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976-80.
54. Hypertension Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. Five-year findings of the Hypertension Detection and Follow-up Program. Hypertension. 1984;6:I198-206.
55. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality in participants in the Hypertension Detection and Follow-up Program. JAMA. 1988;259:2113-22.
56. Hypertension Detection and Follow-up Program Cooperative Group. Patient participation in a hypertension control program. JAMA. 1978;239:1507-14.
57. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Willams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253:3263-7.
58. Curb JD, Borhani NO, Schnaper H, Kass E, Entwisle G, Willams W, et al. Detection and treatment of hypertension in older individuals. Am J Epidemol. 1985;121:371-6.
59. Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Schulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation. 1987;75:340-6.
60. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-8.
61. The Management Committee. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261-7.
62. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Med J Aust. 1981;2:398-402.
63. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985:1:1349-54.
64. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Efficacy of antihypertensive treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet. 1986;2:589-92.
65. Coope J, Warrender TS. Randomized trial of treatment of hypertension in the elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293:1145-8.
66. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial of prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1988;41:1197-208.
67. Hulley SB, Furberg CD, Gurland B, McDonald R, Perry HM, Schnaper HW, et al. Systolic Hypertension in the Elderly Program (SHEP): Antihypertensive efficacy of clorthalidone. Am J Cardiol. 1985;56:913-20.
68. Borhani NO, Applegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, et al. Systolic hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension. 1991;17(3 Suppl):II2-15.
69. Black HR, Curb JD, Pressel S, Probstfield JL. Systolic Hypertension in the Elderly Program (SHEP): Baseline characteristics of the randomized sample. Hypertension. 1991;17(3 Suppl):II171.
70. Wittes J, Davis B, Berge K, Cohen JD, Grimm RH Jr, Hawkins CM, et al. Systolic Hypertension in the Elderly Program (SHEP). Part 10: Analysis. Hypertension. 1991;17(3 Suppl):II 162-7.
71. Petrovitch H, Byington R, Bailey G, Borhani P, Carmody S, Goodwin L, et al. Systolic Hypertension in the Elderly Program (SHEP). Part 2: Screening and recruitment. Hypertension. 1991;17(3 Suppl):II16-23.
72. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-16.
73. Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry. J. Cardiovasc Pharmacol. 1985;7(Suppl 2):S5-9.
74. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
75. Sacks HS, Chalmers TC, Berk AA, Reitman D. Should mild hypertension be treated? An attempted meta-analysis of the clinical trials. Mt Sinai J Med. 1985;52:265-70.
76. Collins R, Peto R, MacMahon S, Hebert P, Fiebach N, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-38.
77. Coope J. Hypertension in the elderly. J Hypertens. 1987;5:S69-72.
78. O'Malley K, McCormack P, O'Brien ET. Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. J Hypertens Suppl. 1988;6:S33-8.
79. Taylor-Halvorsen K, Burdik E, Colditz GA, Frazier HS, Mosteller F. Combining results from independent investigations. Meta-analysis in clinical research. In: Bailar JC, Mosteller F, eds. Medical Uses of Statistics. Boston: NEJM Books; 1992:413-26.
80. Proceedings of 'Methodologie Issues in Overviews of Randomized Clinical Trials.' The National Heart, Lung and Blood Institute and The National Cancer Institute, Bethesda, Maryland, 15-16 May 1986. Stat Med. 1987;6:217-409.
81. Council on Ethical and Judicial Affairs, American Medical Association. Gender disparities in clinical decision making. JAMA. 1991;266: 559-62.
82. Anastos K, Charney P, Charon RA, Cohen E, Jones CY, Marte C, et al. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287-93.
83. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens. 1990;8:393-405.
84. Bots ML, Grobbee DE, Hofman A. High blood pressure in the elderly. Epidemiol Rev. 1991;13:294-314.
85. Kannel WB. Risk factors in hypertension. J Cardiovasc Pharmacol. 1989;13(Suppl 1):S4-10.
86. Garland C, Barrett-Connor E, Suarez L. Criqui MH. Isolated systolic hypertension and mortality after age 60 years. A prospective population-based study. Am J Epidemiol. 1983;118:365-76.
87. Kannel WB, Wolf PA, McGee DL, Drawer TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke. JAMA. 1981;245:1225-9.
88. Winkler MA, Murphy MB. Isolated systolic hypertension in the elderly [Editorial]. JAMA. 1991;265:3301-2.
89. Oxman AD, Guyatt GH. A consumer's guide to subgroup analysis. Ann Intern Med. 1992;116:78-84.
90. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-14.
91. Staessen J, Faggard R, Van Hoof, Amery A. Mortality in various intervention trials in elderly hypertensive patients: a review. Eur Heart J. 1988;9:215-22.
92. Staessen J, Van Hoof R, Faggard R, Amery A. Epidemiology of treated and untreated hypertension in the elderly. In: Amery A, Staessen J, eds. Hypertension in the Elderly. New York: Elsevier: 1989:320-51.
93. Bonita R. Epidemiology of stroke. Lancet. 1992;339:342-4.
94. Bonita R, Ford MA, Stewart AW. Predicting survival after stroke: a three-year follow-up. Stroke. 1988;19:669-73.
95. Verbrugge LM, Lepkowski JM, Imanaka Y. Comorbidity and its impact on disability. Milbank Q. 1989;67:450-84.
96. Forette F, Boiler F. Hypertension and the risk of dementia in the elderly. Am J Med. 1991;90(Suppl 3A):14S-8S.
97. Manton K, Epidemiological, demographic, and social correlates of disability among the elderly. Milbank Q. 1989;67:13-58.
98. Katz S, Branch LG, Branson MH, Papsidero JA, Beck JC, Greer DS. Active life expectancy. N Engl J Med. 1983;309:1218-24.
99. Viscioli CM, Ostfeld A. Epidemiology of hypertension in the elderly. In Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press;1990:191-202.
100. O'Kelly BF, Massie BM, Tubau JF, Szlachcic J. Coronary morbidity and mortality, pre-existing silent coronary artery disease, and mild hypertension. Ann Intern Med. 1989;110:1017-26.
101. Ekbom T, Lindholm L, Odén A, Dalhof B, Hansson L, Scherstén B, et al. Blood pressure does not predict mortality in the elderly. J Hypertens Suppl. 1988;6:S626-8.
102. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error, and sample size in the design and interpretation of randomized controlled trial. Survey of two sets of "negative" trials. In: Bailar J, Mosteller F, eds. Boston: NEJM Books; 1992:357-73.
103. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J. 1985;109:581-5.
104. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-95.
105. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-4.
106. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med. 1992;326:251-4.
107. Leonetti G, Cuspidi C, Fastidio M, Lonati L, Chianca R. Arterial hypertension as a risk factor in the elderly and its treatment. J Hypertens Suppl. 1992;10:S3-7.
108. Celis H, Fagard R, Staessen J, Thijs L, Amery A. The older hypertensive. Assessment and treatment. Neth J Med. 1993;43:S66-77.
109. Agresti E. Analysis of Ordinal Categorical Data. New York: Wiley and Sons;1984:247-50.
110. Fleiss JL. Stastical Methods for Rates and Proportions. New York: Wiley and Sons: 1981;67.